{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"The cumulative incidence of transplant related mortality will be estimated using Kalbfleisch-Prentice method. Deaths before day 100 because of other reasons are the competing risk events.","groups":[{"description":"Participants undergo a conditioning regimen with cyclophosphamide, fludarabine, aldesleukin (interleukin-2), natural killer cell therapy, anti-thymocyte globulin, rituximab, thiotepa, and melphalan prior to transplantation of T-cell depleted HPC transplant on day 0 and CD45RA-depleted HPC transplant on day 1. Beginning Day 6 post-transplant, patients receive G-CSF daily until ANC recovers to normal level.\n\nCyclophosphamide: Given intravenously (IV)\n\nFludarabine: Given IV\n\nG-CSF: Given IV or subcutaneously (SQ)\n\nInterleukin-2: Given SQ\n\nMelphalan: Given IV\n\nThiotepa: Given IV\n\nRituximab: Given IV\n\nNatural killer cell therapy: Given IV\n\nT-cell depleted HPC transplant: T-cell depleted hematopoietic stem cells will be infused on day 0.\n\nCD45RA-depleted HPC transplant: CD45RA depleted stem cells will be infused on day 1.","id":"OG000","title":"Participants"}],"paramType":"NUMBER","populationDescription":"All six participants who received the protocol-defined treatment were evaluable for this analysis. One participant died of a non-transplant related cause (leukemia) prior to day 100. Although this participant did not complete the study to Day 100 post-transplantation, they were still evaluable for TRM.","reportingStatus":"POSTED","timeFrame":"100 days post transplantation","title":"Rate of Transplant-related Mortality (TRM)","type":"SECONDARY","unitOfMeasure":"participants"}